JP2007508316A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007508316A5 JP2007508316A5 JP2006534418A JP2006534418A JP2007508316A5 JP 2007508316 A5 JP2007508316 A5 JP 2007508316A5 JP 2006534418 A JP2006534418 A JP 2006534418A JP 2006534418 A JP2006534418 A JP 2006534418A JP 2007508316 A5 JP2007508316 A5 JP 2007508316A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- substance according
- substance
- overexpression
- erbb2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51060403P | 2003-10-10 | 2003-10-10 | |
| PCT/US2004/033355 WO2005034879A2 (en) | 2003-10-10 | 2004-10-08 | Treatment of diseases involving erbb2 kinase overexpression |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007508316A JP2007508316A (ja) | 2007-04-05 |
| JP2007508316A5 true JP2007508316A5 (cg-RX-API-DMAC7.html) | 2007-11-29 |
Family
ID=34435110
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006534418A Abandoned JP2007508316A (ja) | 2003-10-10 | 2004-10-08 | ＥｒｂＢ２キナーゼ過剰発現に関連する病気の治療 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20050245601A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1670455A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2007508316A (cg-RX-API-DMAC7.html) |
| CN (1) | CN1889944A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2004280257A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2541548A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL174763A0 (cg-RX-API-DMAC7.html) |
| RU (1) | RU2006115615A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2005034879A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2435578C2 (ru) * | 2005-06-29 | 2011-12-10 | Марс, Инкорпорейтед | Возбуждение вазодилатации периферических кровеносных сосудов |
| EP2258358A3 (en) | 2005-08-26 | 2011-09-07 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
| EP2275095A3 (en) | 2005-08-26 | 2011-08-17 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
| EP1940389A2 (en) | 2005-10-21 | 2008-07-09 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
| AU2006308889A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | GABA receptor mediated modulation of neurogenesis |
| AU2006331531B2 (en) * | 2005-12-23 | 2013-01-31 | Mars, Incorporated | Skin protection and improvement |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| JP2009536667A (ja) | 2006-05-09 | 2009-10-15 | ブレインセルス，インコーポレイティド | ５ｈｔ受容体介在性の神経新生 |
| EP2382975A3 (en) | 2006-05-09 | 2012-02-29 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| AU2007292848A1 (en) * | 2006-09-08 | 2008-03-13 | Braincells, Inc. | Combinations containing a 4-acylaminopyridine derivative |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| US20100254996A1 (en) * | 2007-06-18 | 2010-10-07 | Medimmune, Llc | Synergistic treatment of cells that express epha2 and erbb2 |
| WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5554645A (en) * | 1994-10-03 | 1996-09-10 | Mars, Incorporated | Antineoplastic cocoa extracts and methods for making and using the same |
| WO1997036497A2 (en) * | 1996-04-02 | 1997-10-09 | Mars, Incorporated | Cocoa extract compounds and methods for making and using the same |
| US6297273B1 (en) * | 1996-04-02 | 2001-10-02 | Mars, Inc. | Use of cocoa solids having high cocoa polyphenol content in tabletting compositions and capsule filling compositions |
| US6207842B1 (en) * | 1997-10-09 | 2001-03-27 | Mars Incorporated | Process for preparing procyanidin(4-6 or 4-8) oligomers and their derivatives |
| US6156912A (en) * | 1999-04-09 | 2000-12-05 | Mars, Incorporated | 88, 66, and 68 catechin and epicatechin dimers and methods for their preparation |
| US7015338B1 (en) * | 1999-04-15 | 2006-03-21 | Mars Incorporated | Synthetic methods for preparing procyanidin oligomers |
-
2004
- 2004-10-08 RU RU2006115615/14A patent/RU2006115615A/ru not_active Application Discontinuation
- 2004-10-08 EP EP04809906A patent/EP1670455A4/en not_active Withdrawn
- 2004-10-08 US US10/961,992 patent/US20050245601A1/en not_active Abandoned
- 2004-10-08 CA CA002541548A patent/CA2541548A1/en not_active Abandoned
- 2004-10-08 CN CNA2004800362204A patent/CN1889944A/zh active Pending
- 2004-10-08 WO PCT/US2004/033355 patent/WO2005034879A2/en not_active Ceased
- 2004-10-08 AU AU2004280257A patent/AU2004280257A1/en not_active Abandoned
- 2004-10-08 JP JP2006534418A patent/JP2007508316A/ja not_active Abandoned
-
2006
- 2006-04-03 IL IL174763A patent/IL174763A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007508316A5 (cg-RX-API-DMAC7.html) | ||
| RU2365372C2 (ru) | Циклические ингибиторы протеинтирозинкиназ | |
| Cheng et al. | The ligation of aspirin to cisplatin demonstrates significant synergistic effects on tumor cells | |
| WO2008008315A3 (en) | Compositions and methods for inhibiting growth of smad4-deficient cancers | |
| TW200628469A (en) | Disubstituted pyrazolobenzodiazepines | |
| IL184872A0 (en) | Pyrazole derivatives, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments for treatment and prevention of cancers | |
| IL185063A0 (en) | Pyrazole derivatives, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments for treatment and prevention of cancers | |
| JP2010501572A5 (cg-RX-API-DMAC7.html) | ||
| JP2020511467A5 (cg-RX-API-DMAC7.html) | ||
| JP2010523670A5 (cg-RX-API-DMAC7.html) | ||
| ME00937B (me) | Kombinovane terapije koje sadrže hinoksalinske inhibitore pi3k-alfa za upotrebu u liječenju kancera | |
| MX2007002398A (es) | Nuevas composiciones farmaceuticas para el tratamiento de cancer. | |
| CY1112570T1 (el) | Θεραπεια καρκινων με μετασταση | |
| JP2010540556A5 (cg-RX-API-DMAC7.html) | ||
| UA107675C2 (xx) | Застосування n-(4-((3-(2-аміно-4-піримідиніл)-2-піридиніл)окси)феніл)-4-(4-метил-2-тієніл)-1-фталазинаміну для лікування раку, рефрактерного до лікування протираковим агентом | |
| MX2007003104A (es) | Nuevos derivados de ftalazinona, como inhibidores de cinasa aurora-a. | |
| RU2006115615A (ru) | Лечение заболеваний, в патогенез которых вовлечена гиперэкспрессия киназы erbb2 | |
| ATE499372T1 (de) | Azabenzimidalzolderivate, ihre herstellung und ihre verwendung als antikrebsmittel | |
| WO2005085188A3 (en) | Compounds and methods for anti-tumor therapy | |
| JP2005525397A5 (cg-RX-API-DMAC7.html) | ||
| WO2007044450A3 (en) | Compositions and methods for the treatment of cancer | |
| Park et al. | Anticancer effects of genistein, green tea catechins, and cordycepin on oral squamous cell carcinoma | |
| ATE435224T1 (de) | Neue piperidinsubstituierte diaminothiazole | |
| CA2656005A1 (en) | Chemotherapeutic compounds for selectively targeting tumor cells with fr type receptors | |
| WO2011076095A8 (en) | Methods and compositions related to reduced met phosphorylation by leukocyte cell-derived chemotaxin 2 in tumor cells |